Extended Data Fig. 5: Antibody responses against vaccine-matched antigens and viruses elicited by 2018–2019 vaccines.
From: Quadrivalent influenza nanoparticle vaccines induce broad protection
a, Immunization scheme. The commercial QIV, qsCocktail-I53_dn5 and qsMosaic-I53_dn5 vaccines used in this study comprised the 2018–2019 vaccine strains recommended by the WHO. Sequences for the HA-I53_dn5B fusion proteins—H1-I53_dn5, SG16-I53_dn5 (updated H3), B/Yam-I53_dn5, and CO17-I53_dn5 (updated B/Vic)—are provided in Supplementary Table 1. All immunizations were given intramuscularly with AddaVax. Groups of BALB/cJ mice (n = 10) were used. b–d, HA-specific antibody titres (b), HAI assay (c) and microneutralization titres (d) in immune sera. Microneutralization titres are reported as IC50 values. e, Heterosubtypic HA-specific antibody titres in immune sera. Each symbol represents an individual animal and the horizontal bar indicates the geometric mean of the group. P values were determined by nonparametric Kruskal–Wallis tests with Dunn’s multiple comparisons. The animal experiment was performed once.
